Grants and Contributions:
Title:
Formulation development, bioavailability analysis, and assessment of AP-002 anti-osteoporosis activity in vivo
Agreement Number:
919883
Agreement Value:
$430,500.00
Agreement Date:
Jan 1, 2019 - Mar 31, 2020
Description:
This project will assess the anti-bone resorption activity of AP-002 in vivo in a rat osteoporosis model.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Vancouver, British Columbia, CA V6E 3P3
Reference Number:
172-2018-2019-Q4-919883
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
765028691
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The total amended value is 50,000 dollars.
Amendment Date
Mar 23, 2020
Recipient's Legal Name:
Altum Pharmaceuticals Inc.
Federal Riding Name:
Vancouver South
Federal Riding Number:
59040
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
325410
Amendments: